**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 21, 2021**

**NextCure, Inc.**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | (Exact name of registrant as specified in charter) |  |
| **Delaware** | **001-38905** |  | **47-5231247** |
| (State or other jurisdiction |  | (Commission |  | (IRS Employer |
| of incorporation) |  | File Number) | Identification No.) |
| **9000 Virginia Manor Road, Suite 200** |  |
| **Beltsville, Maryland** |  |  |  |  |  | **20705** |
| (Address of principal executive offices) |  |  | (Zip Code) |
|  | **(240) 399-4900** |  |  |
|  | Registrant’s telephone number, including area code |  |

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

* Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
* Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
* Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
* Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

|  |  |  |
| --- | --- | --- |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value per share | NXTC | Nasdaq Global Select Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 21, 2021, Dr. Briggs Morrison notified NextCure, Inc. (the “Company”) of his resignation from the Board of Directors, effective April 1, 2021. Dr. Morrison’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NEXTCURE, INC.**

Date: February 24, 2021

/s/ Steven P. Cobourn



Steven P. Cobourn

Chief Financial Officer

